High-Dose Therapy in Treatment-Refractory Psychosis: A Retrospective Study.
Prim Care Companion CNS Disord
; 24(6)2022 Nov 24.
Article
em En
| MEDLINE
| ID: mdl-36441985
ABSTRACT
Objective:
To examine the impact of antipsychotic dose adjustments (mainly reduction) on the efficacy and tolerability of antipsychotic medications (APMs) to facilitate hospital discharge in long-term hospitalized forensic patients with treatment-refractory psychosis.Methods:
This was a retrospective review of the medical charts of 22 patients with psychosis who were discharged from January 2020 to August 2020 from a long-term state psychiatric facility after restoration of their competency to stand trial. Due to the lack of specific guidelines, the high-dose therapy was defined as a dose ≥ 50% above the average package insert dose. The primary outcome was discharge time after the antipsychotic dosing adjustments.Results:
Sixty-eight percent of subjects, who were hospitalized for a mean ± SD total of 11.6 ± 5.3 months, were discharged after 2.3 ± 0.78 months of 44.4% antipsychotic dose reduction. Two patients, who were hospitalized for 14.5 ± 6.7 months, were discharged after 4 months of optimizing their subtherapeutic doses. Five patients, who were already receiving effective dosages, were discharged after a total hospital duration of 6.8 ± 2.17 months.Conclusions:
The results from this study extend the finding of beneficial effects of antipsychotic dose reduction from prior reports to the forensic population.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Transtornos Psicóticos
/
Antipsicóticos
Tipo de estudo:
Guideline
/
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Prim Care Companion CNS Disord
Ano de publicação:
2022
Tipo de documento:
Article